What is the Most Cost-Effective Plaque Psoriasis Treatment?

Tildrakizumab was recently found to be a more cost-effective option than most of its competitors in a comparative trial involving patients with moderate to severe plaque psoriasis.

In new data presented at the American Academy of Dermatology (AAD) 2019 Annual Meeting in Washington, DC, this week, a team of investigators from the US, UK, and Sweden reported that interleukin 23 (IL-23)-targeting therapy tildrakizumab was among the most cost-effective first-line therapy for plaque psoriasis care that includes fellow humanized monoclonal antibodies adalimumab, brodalumab, guselkumab, infliximab, ixekizumab, secukinumab, and ustenkinumab.

The trial, which also showed the recently-approved therapy’s cost-effectiveness compared to apremilast and etanercept, has implications to the approximate 1.7 million insured US patients burdened with the chronic condition.

Tildrakizumab (ILUMYA) was approved by the FDA for the treatment of adults with moderate to severe plaque psoriasis who are eligible for systemic therapy or phototherapy, in March 2018. The Sun Pharma therapy was approved on the basis of the phase 3 reSURFACE 1 and 2 clinical trial results, showing improved patient skin clearance via the Psoriasis Area Sensitivity Index (PASI).

The IL-23 inhibitor prevents the protein’s interaction with its receptor, therefore block pro-inflammatory cytokine and chemokine release.

Investigators adopted a Markov model consisting of 4 PASI response-based health states for their cost-effectiveness trial. Their 10-year analysis assessed incremental cost per quality-adjusted life-years (QALYs) gained for each first-line therapy compared with a mix of topical therapy, phototherapy, or other systemic therapy.

They also analyzed scenarios to understand the cost impact of adverse events, including hospitalizations due to severe infection and nonmelanoma skin cancer, among others. Indirect costs and different treatment pathways for first-line treatment non-responsiveness were also assessed.

Drug costs were calculated based on wholesale acquisition costs, and direct medical costs included drug and administration costs, laboratory costs, and clinic visits costs.

Though it was found to be among the costliest therapies in year 1 of patient use, tildrakizumab was the fourth-lowest costing drug in year 2 and beyond, investigators reported. Among monoclonal antibodies, it was the second-best therapy in costs. Infliximab, apremilast, and brodalumab were the lowest-cost therapies assessed, respectively.

Per incremental costs per QALY gained, tildrakizumab again fared better than secukinumab, guselkumab, ixekizumab, adalimumab, ustekinumab, and etanercept—but worse than brodalumab, infliximab, and apremilast, respectively. Across the multiple cost scenarios considered, the treatment costs were similar to the incremental costs.

Investigators concluded that tildrakizumab, as a first-line therapy for plaque psoriasis, is more cost-effective measure than guselkumab, secukinumab, izekizumab, ustekinumab, adalimumab, or etanercept.

The study, “Cost-effectiveness of Tildrakizumab in US Patients with Moderate-to-Severe Plaque Psoriasis,” was presented at AAD 2019.
 

This article was originally published by MD Magazine.




Stay up to date on the latest news in specialty pharmacy by getting Specialty Pharmacy Times in your mailbox or inbox for free!

Click here to sign up for free for the bi-monthly Specialty Pharmacy Times print journal delivered to your address.

Click here to sign up for our email newsletters delivered every Monday, Wednesday, and Friday, in addition to breaking news alerts.

Click here to follow us on Facebook. 

Click here to follow us on Twitter. 

Click here to join our LinkedIn group. 


Related Articles

Patients with psoriasis reported frequent use of complementary and alternative treatments when their initial therapies did not help or had adverse effects.
As young patients with bone cancer are often treated with high doses of chemotherapy before and after surgery, researchers wanted to develop gentler treatment options.
Midazolam (Nayzilam) is indicated for seizures that are distinct from a patient's usual seizure pattern, in individuals age 12 years and older with epilepsy.
Company Profile >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Advertise
Careers
Contact Us
Terms & Conditions
Privacy
MJH Associates >
Pharmacy Times
OTCGuide
American Journal of Managed Care
Cure
MD Magazine
ONCLive
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2019
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.
 

$vacMongoViewPlus$